Trial Profile
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 05 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 14 Jul 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2019 as reported by ClinicalTrials.gov record.
- 14 Jul 2015 Planned initiation date changed from 1 Feb 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.